Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Niagen Bioscience, Inc.
Bear Case (25th pct.)
-32.0% vs price
Base Case (Median)
-26.0% vs price
Bull Case (75th pct.)
0.0% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $2.23 | -25.8% | High (40%) |
| PE Comparable | $3.98 | 32.6% | Medium (25%) |
| Graham Number | $1.98 | -34.1% | Medium (40%) |
| EV/EBITDA | $3.26 | 8.6% | Medium (20%) |
| EV/FCF | $2.21 | -26.3% | Medium (20%) |
| Earnings Power Value | $1.23 | -59.0% | Medium (50%) |
Based on 6 out of 7 methods, NAGE appears fairly valued at the current price of $3.00. The base case fair value of $2.22 implies 26.0% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.